Evercore ISI Group Maintains Outperform on Edgewise Therapeutics, Raises Price Target to $55
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
Evercore ISI Group analyst Cory Kasimov maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Outperform and raises the price target from $45 to $55.
Evercore ISI Group analyst Cory Kasimov maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Outperform and raises the price target from $45 to $55.